Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03935919
Other study ID # GluPop
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 13, 2019
Est. completion date March 1, 2020

Study information

Verified date April 2020
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study it to assess whether the continuous glucose monitor system Dexcom G6® can be reliably used for perioperative glucose monitoring in 20 prediabetic or diabetic patients undergoing abdominal surgery in terms of data continuity, accuracy and patient tolerability.


Description:

The current recommended method for monitoring glucose control is bedside point of care capillary blood glucose testing. A significant limitation for this method is the frequency by which blood glucose testing is typically performed, at most 4-6 times daily. Continuous glucose monitoring (CGM) provides an alternative approach to measure glucose values with the advantage of greater frequency of monitoring as it is measured every few minutes.

Whilst CGM use in the outpatient setting is rising and has demonstrated benefits on glycaemic control, the accuracy of these devices perioperatively is less investigated. In this study the sixth-generation factory-calibrated real-time Dexcom G6® system will be used as a CGM and its glucose values perioperatively will be compared to the capillary glucose values which will be measured simultaneously by the Accu-Check Inform II (Roche Diagnostics) point-of-care blood glucose meter.

The Investigators aim to assess the feasibility and accuracy of perioperative CGM.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 1, 2020
Est. primary completion date February 26, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Aged =18 years

- Pre-diabetic (HbA1c 5.7-6.5%) or diabetic (regardless of aetiology)

- Scheduled to have elective abdominal surgery at the University Hospital Bern

- Surgery duration >2 hours

Exclusion criteria:

- Planned MRI procedure during hospitalization

- Inability to follow procedures

- Incapacity to give informed consent

- Presence of extensive skin abnormalities at the sensor insertion site (upper arm)

- Known allergic/irritative skin reactions to dressings/adhesives

- Haematocrit values outside the normal range

- Patients with immunosuppression defined as neutrophil count <0.5x10^9/L

- Patients on isolation precautions (contact, droplet, airborne)

- Pregnancy or breast-feeding

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern University Hospital Bern

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensor accuracy in the perioperative period Mean Absolute Relative Difference (MARD) between Dexcom G6 sensor glucose values and capillary blood glucose values measured using the Accu-Check Inform II meter in the perioperative period (%) 1 day
Secondary Mean absolute relative difference between sensor glucose and reference glucose in the preoperative period (%) Mean absolute relative difference between sensor glucose and reference glucose (for reference values >3.9 and <10.0mmol/l, for reference values =3.9mmol/l, for reference values =10.0mmol/l) in the preoperative period (%) 1 week
Secondary Mean absolute relative difference between sensor glucose and reference glucose in the postoperative period (%) Mean absolute relative difference between sensor glucose and reference glucose (for reference values >3.9 and <10.0mmol/l, for reference values =3.9mmol/l, for reference values =10.0mmol/l) in the postoperative period (%) 1-2 weeks
Secondary Median absolute relative difference between sensor glucose and reference glucose in the preoperative period (%) Median absolute relative difference between sensor glucose and reference glucose (for reference values >3.9 and <10.0mmol/l, for reference values =3.9mmol/l, for reference values =10.0mmol/l) in the preoperative period (%) 1 week
Secondary Median absolute relative difference between sensor glucose and reference glucose in the perioperative period (%) Median absolute relative difference between sensor glucose and reference glucose (for reference values >3.9 and <10.0mmol/l, for reference values =3.9mmol/l, for reference values =10.0mmol/l) in the perioperative period (%) 1 day
Secondary Median absolute relative difference between sensor glucose and reference glucose in the postoperative period (%) Median absolute relative difference between sensor glucose and reference glucose (for reference values >3.9 and <10.0mmol/l, for reference values =3.9mmol/l, for reference values =10.0mmol/l) in the postoperative period (%) 1-2 weeks
Secondary Percentage of sensor measurements in the preoperative period within the limits specified by the International Organization of Standardization (ISO) : 15197:2013 criteria Proportion of sensor measurements in the preoperative period within ±15% of reference glucose if the reference value is =5.6mmol/l and within 0.8mmol/l if the reference values is <5.6mmol/l (%) 1 week
Secondary Percentage of sensor measurements in the perioperative period within the limits specified by the ISO: 15197:2013 criteria Proportion of sensor measurements in the perioperative period within ±15% of reference glucose if the reference value is =5.6mmol/l and within 0.8mmol/l if the reference values is <5.6mmol/l (%) 1 day
Secondary Percentage of sensor measurements in the postoperative period within the limits specified by the ISO: 15197:2013 criteria Proportion of sensor measurements in the postoperative period within ±15% of reference glucose if the reference value is =5.6mmol/l and within 0.8mmol/l if the reference values is <5.6mmol/l (%) 1-2 weeks
Secondary Bias and 95% limits of agreement of sensor glucose compared to reference glucose in the preoperative period Calculation of bias and 95% limits of agreement of sensor glucose compared to reference glucose in the preoperative period 1 week
Secondary Bias and 95% limits of agreement of sensor glucose compared to reference glucose in the perioperative period Calculation of bias and 95% limits of agreement of sensor glucose compared to reference glucose in the perioperative period 1 day
Secondary Bias and 95% limits of agreement of sensor glucose compared to reference glucose in the postoperative period Calculation of bias and 95% limits of agreement of sensor glucose compared to reference glucose in the postoperative period 1-2 weeks
Secondary Clarke error grid analysis in the preoperative period Proportion of sensor glucose values in Clark's error grid zones (A, B, A+B, C, D, E)in the preoperative period (%) 1 week
Secondary Clarke error grid analysis in the perioperative period Proportion of sensor glucose values in Clark's error grid zones (A, B, A+B, C, D, E) in the perioperative period (%) 1 day
Secondary Clarke error grid analysis in the postoperative period Proportion of sensor glucose values in Clark's error grid zones (A, B, A+B, C, D, E) in the postoperative period (%) 1-2 weeks
Secondary Sensor availability in the preoperative period (%) Proportion of study period with available sensor glucose values in the preoperative period 1 week
Secondary Sensor availability in the perioperative period (%) Proportion of study period with available sensor glucose values in the perioperative period 1 day
Secondary Sensor availability in the postoperative period (%) Proportion of study period with available sensor glucose values in the postoperative period 1-2 weeks
Secondary Number of sensor replacement events in the preoperative period Number of times that the sensor needed to be replaced in the preoperative period 1 week
Secondary Number of sensor replacement events in the perioperative period Number of times that the sensor needed to be replaced in the perioperative period 1 day
Secondary Number of sensor replacement events in the postoperative period Number of times that the sensor needed to be replaced in the postoperative period 1-2 weeks
Secondary Number of adverse device effects in the preoperative period Adverse event related to the use of study devices (e.g. skin irritative and allergic reactions, bleeding) in the preoperative period 1 week
Secondary Number of adverse device effects in the perioperative period Adverse event related to the use of study devices (e.g. skin irritative and allergic reactions, bleeding) in the perioperative period 1 day
Secondary Number of adverse device effects in the postoperative period Adverse event related to the use of study devices (e.g. skin irritative and allergic reactions, bleeding) in the postoperative period 1-2 weeks
Secondary Percentage of time in the preoperative period with sensor glucose levels within target range Proportion of time in the preoperative period with sensor glucose levels between 3.9-10.0mmol/l 1 week
Secondary Percentage of time in the perioperative period with sensor glucose levels within target range Proportion of time in the perioperative period with sensor glucose levels between 3.9-10.0mmol/l 1 day
Secondary Percentage of time in the postoperative period with sensor glucose levels within target range Proportion of time in the postoperative period with sensor glucose levels between 3.9-10.0mmol/l 1-2 weeks
Secondary Percentage of time in the preoperative period with sensor glucose levels below target range Proportion of time in the preoperative period with sensor glucose levels below 3.9mmol/l 1 week
Secondary Percentage of time in the perioperative period with sensor glucose levels below target range Proportion of time in the perioperative period with sensor glucose levels below 3.9mmol/l 1 day
Secondary Percentage of time in the postoperative period with sensor glucose levels below target range Proportion of time in the postoperative period with sensor glucose levels below 3.9mmol/l 1-2 weeks
Secondary Percentage of time in the preoperative period with sensor glucose levels above target range Proportion of time in the preoperative period with sensor glucose levels above 10.0mmol/l 1 week
Secondary Percentage of time in the perioperative period with sensor glucose levels above target range Proportion of time in the perioperative period with sensor glucose levels above 10.0mmol/l 1 day
Secondary Percentage of time in the postoperative period with sensor glucose levels above target range Proportion of time in the postoperative period with sensor glucose levels above 10.0mmol/l 1-2 weeks
Secondary Mean sensor glucose value in the preoperative period Mean value of the sensor glucose levels in the preoperative period 1 week
Secondary Mean sensor glucose value in the perioperative period Mean value of the sensor glucose levels in the perioperative period 1 day
Secondary Mean sensor glucose value in the postoperative period Mean value of the sensor glucose levels in the postoperative period 1-2 weeks
Secondary Standard deviation of sensor glucose levels in the preoperative period Standard Deviation of the sensor glucose levels in the preoperative period 1 week
Secondary Standard deviation of sensor glucose levels in the perioperative period Standard Deviation of the sensor glucose levels in the perioperative period 1 day
Secondary Standard deviation of sensor glucose levels in the postoperative period Standard Deviation of the sensor glucose levels in the postoperative period 1-2 weeks
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A